Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lithium versus quetiapine augmentation for treatment-resistant depression
2016-001637-27Phase 4Unknown
- Sponsor
- South London and Maudsley NHS Foundation Trust
- Start
- Jul 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in major depressive disorder (MDD) comparing Lithium augmentation with Quetiapine augmentation (2 arms). Primary endpoints: Time to all-cause treatment discontinuation and Longitudinal depressive symptom severity. Status: unknown.
02
Drugs
lithiumquetiapine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2016-001637-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001637-27.